AC 262271

Drug Profile

AC 262271

Alternative Names: AC-262271

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma

Most Recent Events

  • 12 May 2016 Phase I development is ongoing in USA
  • 30 Sep 2015 Allergan terminates collaboration agreement with ACADIA Pharmaceuticals for development of muscarinic therapeutics for Glaucoma (ACADIA Pharmaceuticals 10-Q, September 2015)
  • 26 Mar 2014 Phase I development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top